WO2011007612A1 - 経口性抗炎症剤及び経口性抗炎症ペプチド - Google Patents
経口性抗炎症剤及び経口性抗炎症ペプチド Download PDFInfo
- Publication number
- WO2011007612A1 WO2011007612A1 PCT/JP2010/057993 JP2010057993W WO2011007612A1 WO 2011007612 A1 WO2011007612 A1 WO 2011007612A1 JP 2010057993 W JP2010057993 W JP 2010057993W WO 2011007612 A1 WO2011007612 A1 WO 2011007612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammatory
- peptide
- amino acid
- weight
- molecular weight
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a peptide having an anti-inflammatory function.
- the present invention also relates to novel tripeptides such as Phe-Leu-Val and Val-Pro-Tyr having an anti-inflammatory function.
- Patent document 1 exists as an application regarding the peptide which has an anti-inflammatory function.
- This application describes a great variety of di- and tripeptides including Arg, and also describes a number of physiological effects besides anti-inflammatory function. However, these are premised on the production by synthesis, and it is difficult to say that safety is sufficiently established. In addition, no description about Phe-Leu-Val and Val-Pro-Tyr is found.
- Patent Document 2 discloses an application for an effect on gastrointestinal ulcer that is not directly related to an anti-inflammatory function but is an ingredient derived from food and is also effective in the present invention. However, this is only a description of the effect on the enzyme degradation product of cheese, and no description of a specific active substance is found.
- cheese has a strong palatability due to its unique flavor, and it is highly possible that it has a stronger flavor by enzymatic degradation.
- milk protein is originally a protein that tends to have a bitter taste due to enzymatic degradation. Therefore, there is a limit when the use as a food material is also assumed.
- An object of the present invention is to provide a pharmaceutical composition or food having an anti-inflammatory function, which is effective for inflammatory diseases such as inflammatory bowel disease, and a treatment method using the composition.
- Another object of the present invention is to provide a material having an anti-inflammatory function, which is effective for inflammatory diseases such as inflammatory bowel disease, and a therapeutic method using the material. It is particularly desirable if it can be used as a general-purpose food material.
- the present inventor in earnest examination in view of the above situation, orally administered soy peptide prepared to have a certain molecular weight distribution by enzymatic degradation to pigs in which intestinal inflammation was induced with dextran sulfate.
- intestinal inflammation is suppressed and have reached the present invention.
- the secretion of inflammatory cytokines TNF- ⁇ , IL-6, IL-17
- the soybean peptide of the present invention has a function of suppressing the secretion of these inflammatory cytokines, thereby suppressing inflammation.
- the tripeptides with the amino acid sequence of phenylalanine-leucine-valine or valine-proline-tyrosine were found. It has been found that those having the sequence are absorbed from intestinal epithelial cells and the like, stimulate the immune system, and express the anti-inflammatory cytokine secretion inhibitory function described above. That is, the present inventors have found that a tripeptide having an amino acid sequence of phenylalanine-leucine-valine or valine-proline-tyrosine can be expected as an effective material for alleviating inflammatory bowel disease and the like.
- the present invention is a soy peptide having a certain molecular weight distribution and having an anti-inflammatory function, which is an oral anti-inflammatory composition, a pharmaceutical product, a food, and a feed comprising these as active ingredients, and the peptide is used. It relates to the treatment of inflammatory diseases. Furthermore, the present invention is a novel tripeptide having an anti-inflammatory function consisting of an amino acid sequence of phenylalanine-leucine-valine or valine-proline-tyrosine, which is used as an active ingredient in oral anti-inflammatory compositions, pharmaceuticals, and feeds. And a method for treating inflammatory diseases using the tripeptide or the like.
- the present invention (1) An oral anti-inflammatory functional agent which is a soy peptide having a molecular weight fraction of 500 or less excluding free amino acids of 40% by weight or more and a free amino acid content of 7% by weight or less. (2) A method for treating inflammation using the anti-inflammatory functional agent according to (1). (3) The oral anti-inflammatory functional agent according to (1), wherein the target disease is intestinal inflammation. (4) A tripeptide represented by the amino acid sequence Phe-Leu-Val. (5) A tripeptide represented by the amino acid sequence Val-Pro-Tyr. (6) An anti-inflammatory functional agent comprising one or more of the tripeptides according to (4) and (5) as an active ingredient.
- a method for treating inflammation comprising one or more of the tripeptides according to (4) and (5) as an active ingredient.
- An inflammatory cytokine secretion inhibitor comprising one or more of the tripeptides according to (4) and (5) as an active ingredient. It is about.
- peptides that are effective for inflammatory diseases such as inflammatory bowel diseases, foods, medicines and feeds containing the peptides.
- the anti-inflammatory composition effective in inflammatory diseases such as an inflammatory bowel disease, and the foodstuff, medicine, and feed containing the said composition are provided.
- the inflammation treatment method using the said tripeptide is provided.
- the molecular weight distribution of the soybean peptide of the present invention requires that 40% by weight or more (excluding free amino acids) be a molecular weight of 500 or less and a free amino acid content be 7% by weight or less. More desirably, 43% by weight or more (excluding free amino acids) is made to have a molecular weight of 500 or less, and the free amino acid content is made to be 6% by weight or less.
- the molecular weight is measured by gel filtration. More specifically, it was measured using a UV detector using a gel filtration column manufactured by TSK. More specifically, the molecular weight was measured by the following method.
- soybean peptide of the present invention when the ratio of the molecular weight of 500 or less is less than 40% by weight or the free amino acid content exceeds 7% by weight, the remarkable effect may be lost.
- a conventionally known method such as enzymatic degradation or acid degradation can be employed.
- enzymatic degradation is more desirable for the safety of manufacturing workers because the reaction can be performed under milder conditions.
- the protease used may be a commercially available one, regardless of animal origin, plant origin, or microbial origin. Specifically, serine protease (animal-derived trypsin, chymotrypsin, microbial-derived subtilisin, carboxypeptidase, etc.), thiol peptidase (plant-derived papain, bromelain, etc.), carboxyprotease (animal-derived pepsin, etc.), metalloprotease (thermolysin) ) Etc. can be used.
- serine protease animal-derived trypsin, chymotrypsin, microbial-derived subtilisin, carboxypeptidase, etc.
- thiol peptidase plant-derived papain, bromelain, etc.
- carboxyprotease animal-derived pepsin, etc.
- metalloprotease thermolysin
- “Samoase” (manufactured by Daiwa Kasei Co., Ltd.), “Biolase” (manufactured by Nagase Chemtech Co., Ltd.), “Sumiteam FP” (manufactured by Shin Nippon Chemical Co., Ltd.) and the like derived from microorganisms.
- the reaction conditions for the enzyme can be appropriately set in consideration of other workability, centering on the optimum reaction conditions for the enzyme to be used.
- commercially available isolated soy protein is used as a substrate, and about 0.5 to 2.0% by weight of enzyme is added to about 3 to 7% by weight solution (pH 5 to 9), and about 30 to 60 ° C. For example.
- Inflammation exerted by the present invention. Inflammation is a symptom that occurs in the process of removing the cause of a cell being damaged by some kind of disorder. When you catch a cold or get injured, inflammation is caused by the removal of viruses or necrotic cells. Inflammation is a sign of removing these causative substances. These viruses and bacteria are called exogenous factors. On the other hand, allergic inflammation due to deposition of cells and tissues in immune complexes produced in the body and inflammation due to abnormal metabolites generated in the body (including gout) are called intrinsic factors. .
- abnormal intestinal immune tolerance which is said to be an abnormality of the intestinal tract immune system related to the immune selection of harmful and innocuous substances (immune tolerance) in the body.
- IBD Crohn's disease
- UC ulcerative bowel disease
- abnormal intestinal immune tolerance is said to be an abnormality of the intestinal tract immune system related to the immune selection of harmful and innocuous substances (immune tolerance) in the body.
- the above-mentioned Crohn's disease and ulcerative bowel disease are recognized as inflammatory bowel diseases, but mild diarrhea, etc. that occurs occasionally when mental stress becomes stronger, is caused by the same mechanism of action. Is expected. In other words, mental external factors such as stress cause abnormalities in the intestinal tract immune system and cause inflammation in the intestinal tract. In fact, many diagnoses of inflammatory bowel disease are reported to start with mild diarrhea, and begin to feel severe symptoms such as melena when they begin to feel intense stress such as work. There is a case. When describing the malfunction of the intestinal tract immune system in IBD, what is generally called naive T cells differentiates into Th1, Th2, called helper T cells, Th17 recently discovered, and the like by various cytokines.
- This helper T cell is an important organ that controls the body's immune function, and it is known that allergic symptoms such as hay fever are caused by this differentiation defect.
- the inflammatory cytokine TNF- ⁇ secreted from this Th1 cell is said to be closely related to CD.
- Th17 is deeply involved in inflammation and IBD, and inflammatory cytokines involved in this differentiation and the like are IL-6 and IL-17.
- drugs for inflammatory bowel disease various adrenocortical hormones, azathioprine, which is an immunosuppressive agent, and infliximab, which has an effect of capturing TNF- ⁇ before binding to a receptor, have already been effective. It shows that the treatment is effective.
- inflammatory bowel disease and the like are symptoms closely related to the immune mechanism, and can be quantitatively grasped by measuring the secretion behavior of TNF- ⁇ , IL-6, IL-17, etc. It is believed that. (International J. of Colorectal Disease, 15, 144-160 (2000)). That is, when secretion of TNF- ⁇ , IL-6, and IL-17 is suppressed, it can be determined that there is an anti-inflammatory effect.
- the anti-inflammatory effect is large, the absolute value of the secretion amount of TNF- ⁇ , IL-6, and IL-17 per specimen tissue weight was measured, and the average value of each cytokine was compared with the control. In this case, if any one of TNF- ⁇ , IL-6, and IL-17 is suppressed by 20% by weight or more, it can be said to be “effective”.
- the term “inflammatory disease” refers to all diseases accompanied by general inflammation, and more specifically refers to inflammatory bowel disease (Inflammatory Bowel Disease: IBD). Specific examples thereof include Crohn's disease (CD) and ulcerative bowel disease (UC).
- IBD Inflammatory Bowel Disease
- CD Crohn's disease
- UC ulcerative bowel disease
- the peptide of the present invention is effective even in mild diseases that are not recognized as diseases, such as sudden diarrhea and abdominal pain as subjective symptoms, as long as inflammation is the cause. In this case, these mild diseases are also included in the “inflammatory bowel disease” in the present invention.
- the peptide of the present invention can be used as a food, medicine or feed, if necessary, mixed with other raw materials as necessary.
- serving as food it can be used by mixing with solid foods such as biscuits, cakes, breads, etc., dissolved in water as beverages, or fluid, semi-solid foods such as yogurt and pudding There is no problem even if they are mixed.
- the peptide of the present invention may be denatured by decomposition or the like due to heat during sterilization of food.
- vitamins, minerals and the like are mixed and used as a supplement.
- When used as a medicine it may be used in combination with a medicine such as an adrenocortical hormone or an immunosuppressant.
- the feed application can be used without being limited to land and fishery.
- the tripeptide having the amino acid sequence of phenylalanine-leucine-valine or valine-proline-tyrosine according to the present invention can be used as a food, pharmaceutical, or feed, if necessary, mixed with other raw materials as necessary.
- the mode of serving as a food is the same as that described for the “peptide”.
- Tripeptides having the amino acid sequence of phenylalanine-leucine-valine (abbreviation: Phe-Leu-Val or FLV) or valine-proline-tyrosine (abbreviation: Val-Pro-Tyr or VPY) of the present invention are generally known. It can be synthesized by the method or separated from the food material.
- FLV has the amino acid sequence at residues 472 to 474 in the 11S globulin A2B1a subunit of soy protein, and can be separated from the soy protein after decomposition by protease treatment or the like.
- Soybean is a material considered to be highly safe from a long history of eating experience, and when separated from food material, it is preferable to use soybean as a raw material.
- VPY is present at residues 153-155 in the A5A4B3 subunit of soy protein 11S globulin.
- the tripeptide having the phenylalanine-leucine-valine or valine-proline-tyrosine sequence of the present invention can be ingested as a peptide mixture containing the tripeptide and exert its effect without being used separately. That is, the anti-inflammatory action possessed by the tripeptide of the present invention exerts its effect even by oral administration.
- enzymatic degradation is more desirable for the safety of manufacturing workers because the reaction can be performed under milder conditions.
- a peptide containing a tripeptide having the sequence phenylalanine-leucine-valine or valine-proline-tyrosine has a molecular weight distribution of 40% by weight or more (excluding free amino acids) and a free amino acid content of 7 or less. It is desirable to make it not more than wt%, more desirably 43 wt% or more (excluding free amino acids) is made to have a molecular weight of 500 or less and the free amino acid content is made to be 6 wt% or less.
- the molecular weight is measured by gel filtration.
- soy peptide having a molecular weight distribution it is possible not only to decompose soy protein by enzymes, but also to combine some separation operation thereafter. Specifically, the precipitate generated by the decomposition operation with an enzyme or the like can be removed by centrifugation, or separation with a UF membrane or the like can be performed. In order to efficiently obtain a peptide having a desired molecular weight distribution, it is often advantageous to use these separation means from the viewpoint of yield and the like.
- a conventionally known method can be used as a method for separating the tripeptide.
- one or more methods selected from techniques such as pH treatment, microfiltration, centrifugation, and electrophoresis can be combined.
- Sumiteam FP (source: Aspergillus sp., Shin Nippon Chemical Industry) was added at 1% by weight per protein and allowed to act at pH 7.5, 58 ° C. for 60 minutes. After the above treatment, the reaction was stopped by heating at 85 ° C. for 20 minutes.
- the resulting insoluble matter was removed by centrifugation and filtration through a membrane filter having a pore size of 1.0 ⁇ m to obtain “Peptide Composition 1”.
- the fraction having a molecular weight of 500 or less excluding free amino acids was 45% by weight, and the free amino acids were 5% by weight.
- the tripeptide content represented by phenylalanine-leucine-valine was measured by HPLC using an ODS column and a PAD detector and found to be 3% by weight.
- Example 1 Comparative Examples 1 and 2
- Example 1 "Prophylaxis or treatment of ulcerative colitis”
- Example 2 Fate was given as drinking water for 5 days (DSS treatment), after which Example 1 fed peptide composition 1 at 250 mg / kg body weight for 5 days, and Comparative Example 1 gave peptide composition 2 at 250 mg / kg body weight for 5 days.
- DSS treatment DSS treatment
- Comparative Example 1 gave peptide composition 2 at 250 mg / kg body weight for 5 days.
- Comparative Example 2 alanine corresponding to the nitrogen content of the peptide was fed.
- Comparative Example 2 corresponds to the control.
- Extract sulfate is a substance that induces intestinal inflammation. International J. of Colorectal Disease, 15, 144-160 (2000)
- cytokines by ELISA TNF- ⁇ and IL-6 were measured using a porcine ELISA kit (R & D system Inc. USA).
- TNF- ⁇ , IL-6, IL-17 The analysis results of TNF- ⁇ , IL-6, and IL-17 are shown in FIGS.
- the amount of TNF- ⁇ secreted was 96% in Comparative Example 1 and 60% in Example 1 when the amount of secretion in Comparative Example 2 was taken as 100%.
- the secretion amount of IL-6 was 113% in Comparative Example 1 and 43% in Example 1, assuming that the secretion amount in Comparative Example 2 was 100%.
- the secretion amount of IL-17 was 86% in Comparative Example 1 and 9% in Example 1 when the secretion amount in Comparative Example 2 was taken as 100%. From the above, in Example 1, both TNF- ⁇ , IL-6, and IL-17 were inhibited by 20% or more of the secreted amount compared to Comparative Example 2, and it was judged that there was an effect.
- Example 1 was determined to be significant (risk rate of 5% or less). Comparative Example 1 was not judged significant.
- -Analysis of peptide in plasma There were three peptide peaks in the plasma of Example 1. The largest peak was analyzed by LC-MS / MS to identify the amino acid sequence of the peptide. As a result, it was a tripeptide having the amino acid sequence of phenylalanine-leucine-valine. Moreover, when the amino acid sequence of the peptide was identified using the same method for the second largest peak, it was a tripeptide having the amino acid sequence of valine-proline-tyrosine.
- FIGS. 6 The microscope picture of the tissue sample of the large intestine of the pig which provided the sample in Example 1 and Comparative Example 2 is shown in FIGS. As shown in FIG. 6, ulcers were hardly confirmed in Example 1, whereas severe ulcers were confirmed in Comparative Example 2 of FIG. (In Comparative Example 1, a serious ulcer similar to Comparative Example 2 was confirmed).
- "Inhibition of inflammatory cytokines by cell experiments using synthetic peptides" FLV and VPY synthesis FLV was synthesized using an organic synthetic chemistry method using phenylalanine, leucine, and valine as raw materials and a carbodiimide-based condensing agent as a catalyst. The synthesis of VPY was performed using an organic synthetic chemistry method using valine, proline and tyrosine as raw materials and a carbodiimide-based condensing agent as a catalyst.
- Example 1 "Discussion" -As in Example 1, in pigs administered with the peptide composition 1, it was confirmed by histological analysis that the occurrence of intestinal ulcers was suppressed or healed. Similarly, in the pig (Comparative Example 1) to which the peptide composition 2 was administered, the same intestinal ulcer as in Comparative Example 2 was confirmed. From this, it was confirmed that the peptide composition 1 contains a component having an inhibitory effect or healing effect on the intestinal ulcer. ⁇ The analysis of swine plasma in Example 1 confirmed that TNF- ⁇ , IL-6, and IL-17 secretion was suppressed, and the occurrence of intestinal ulcers in swine by the currently assumed anti-inflammatory mechanism It was confirmed that suppression or healing occurred.
- a safe oral anti-inflammatory composition, food, medicine and feed that suppresses inflammatory cytokines of TNF- ⁇ , IL-6, and IL-17, which are effective for inflammatory diseases such as inflammatory bowel diseases Is provided.
- an oral anti-inflammatory comprising as an active ingredient a safe food material that suppresses inflammatory cytokines of TNF- ⁇ , IL-6, and IL-17, which is effective for inflammatory diseases such as inflammatory bowel diseases.
- Compositions, foods, medicaments and feeds are provided.
- FIG. 3 is a diagram showing the secretion behavior of TNF- ⁇ in Example 1 and Comparative Examples 1 and 2.
- secretion of TNF- ⁇ was remarkably suppressed.
- FIG. 3 is a diagram showing IL-6 secretion behavior of Example 1 and Comparative Examples 1 and 2.
- IL-6 secretion was remarkably suppressed.
- FIG. 3 is a diagram showing the IL-17 secretion behavior of Example 1 and Comparative Examples 1 and 2.
- IL-17 secretion was remarkably suppressed.
- Comparative Example 1 serious intestinal inflammation similar to Comparative Example 2 was also confirmed.
- 2 is a photomicrograph of a tissue sample of the large intestine of a pig of Example 1.
Abstract
Description
直接抗炎症機能を謳うものではないが、食品由来の成分で、本願発明でも効果が認められる消化管潰瘍への効果を謳う出願として、特許文献2がある。しかしこれはチーズの酵素分解物に関する効果を記載したものに過ぎず、具体的な作用物質についての記載は見られない。またチーズはその独特の風味から嗜好性が強く、酵素分解を行うことで、より強い風味となっている可能性が高い。さらに、乳蛋白は元々、酵素分解により苦味が出やすい蛋白である。よって、食品素材としての利用も想定した場合、制限がある。
更に詳細に調べてみると、当該大豆ペプチドを経口投与した豚の血漿中の炎症性サイトカイン(TNF-α、IL-6、IL-17)の分泌が抑制されていることを見出した。つまり、本発明の大豆ペプチドには、これら炎症性サイトカインの分泌抑制機能があり、これにより、炎症が抑制されていることを見出した。効果の見られた検体に関し、血中のプラズマに存在しているペプチドを分析してみると、フェニルアラニン-ロイシン-バリンないしバリンープロリンーチロシンのアミノ酸配列をもつトリペプチドが発見され、これらのアミノ酸配列をもつものが腸管上皮細胞等から吸収されて、免疫系を刺激し、前述の抗炎症性サイトカインの分泌抑制機能を発現していることを見出した。すなわちフェニルアラニン-ロイシン-バリンないしバリンープロリンーチロシンのアミノ酸配列をもつトリペプチドが炎症性腸疾患等の緩和へ有効な素材として期待できることを見出し本発明にいたった。
さらに本発明はフェニルアラニン-ロイシン-バリンないしバリンープロリンーチロシンのアミノ酸配列からなる抗炎症機能をもつ新規トリペプチドであって、それらを有効成分とする、経口性抗炎症組成物、医薬品、飼料であり、かつ、当該トリペプチド等を用いた炎症性疾患の治療法についてのものである。
すなわち本発明は、
(1)遊離アミノ酸を除く分子量500以下の画分が40重量%以上でありかつ、遊離アミノ酸含量が7重量%以下である、大豆ペプチドである経口性抗炎症機能剤。
(2)(1)記載の抗炎症機能剤を使用する、炎症治療方法。
(3)対象とする疾病が腸管炎症である、(1)記載の経口性抗炎症機能剤。
(4)アミノ酸配列Phe-Leu-Valで示されるトリペプチド。
(5)アミノ酸配列Val-Pro-Tyrで示されるトリペプチド。
(6)(4),(5)記載のトリペプチドの1種以上を有効成分とする、抗炎症機能剤。
(7)(4),(5)記載のトリペプチドの1種以上を有効成分とする、炎症治療方法。
(8)(4),(5)記載のトリペプチドの1種以上を有効成分とする、炎症性サイトカイン分泌抑制剤。
に関するものである。
2種のカラム直列接続によってペプチド用ゲルろ過システムを組み、分子量マーカーとなる既知ペプチドをチャージし、分子量と保持時間の関係において検量線を求めた(表1、図1)。酵素分解した分解物(1%)を10,000×g、10分で遠心した上清を、ゲルろ過用溶媒で2倍希釈し、その5μlをアプライした。各分子量画分の含有量比率%については、全体の吸光度のチャート面積に対する、特定の分子量範囲(時間範囲)の面積の割合によって求めた。(1stカラム:Superdex 75 10/300GL、2ndカラム:Superdex Peptide 7.5/300GL,溶媒:1%SDS/10mMリン酸緩衝液,pH8.0,25℃,流速:0.25ml/min,検出:OD220nm)
表1 分子量標準物質
また、遊離アミノ酸含有量は以下の方法にて分析を行った。
試料(4 mg/ml)を等量の3%スルホサリチル酸に加え、室温で15分間振とうした。10,000rpm 10分間遠心し、得られた上澄を0.45 μmフィルターでろ過し、アミノ酸分析器(日本電子製 JLC500V)にて、遊離アミノ酸を測定した。アミノ酸量はケルダール法にて得られた全粗たん白質に対する量として算出した。
大豆タンパク質を上記のような分子量分布を示すペプチドにするための方法は、酵素分解や酸による分解など、従来から知られている方法を採用することができる。特に酵素による分解では、より温和な条件にて反応を行うことができるため、製造作業者の安全のためなどからより望ましい。
具体的にはセリンプロテアーゼ(動物由来のトリプシン、キモトリプシン、微生物由来のズブチリシン、カルボキシペプチダーゼなど)、チオールペプチダーゼ(植物由来のパパイン、ブロメラインなど)、カルボキシプロテアーゼ(動物由来のペプシンなど)、金属プロテアーゼ(サーモライシン)等を用いることが出来る。より具体的には微生物由来である「サモアーゼ」(大和化成社製)、「ビオプラーゼ」(ナガセケムテック社製)、「スミチームFP」(新日本化学社製)などである。酵素の反応条件は、使用する酵素の最適な反応条件を中心に、その他の作業性などを考慮して適宜設定することができる。たとえば、基質としては市販の分離大豆タンパク質を使用し、この3~7重量%程度の溶液(pH5~9)に対し、酵素を0.5~2.0重量%程度加え、30~60℃程度で反応させる等である。
本発明のフェニルアラニン-ロイシン-バリン(略号:Phe-Leu-ValないしFLV)もしくはバリンープロリンーチロシン(略号:Val-Pro-TyrないしVPY)のアミノ酸配列をもつトリペプチドは一般的に知られた方法により合成することも、また食品素材から分離することもできる。ただ、安全性の点などから、食品から分離したほうが有利な場合もある。食品としては、たとえば、FLVは大豆蛋白質の11SグロブリンのA2B1aサブユニット中の472-474残基に当該アミノ酸配列が存在しており、分離大豆蛋白質からプロテアーゼ処理等により分解後、分離することができる。大豆は長い食経験の歴史から安全性が高いと考えられる素材であり、食品素材から分離する場合も、好ましくは大豆を原料としたほうがよい。同様に、VPYは大豆蛋白質11SグロブリンのA5A4B3サブユニット中の153-155残基に存在する。
大豆蛋白から当該トリペプチドを得ようとする場合、まず大豆蛋白を酵素や酸など、従来から知られている方法により、分解する必要がある。特に酵素による分解では、より温和な条件にて反応を行うことができるため、製造作業者の安全のためなどからより望ましい。
フェニルアラニン-ロイシン-バリンもしくはバリンープロリンーチロシンの配列を持つトリペプチドを含むペプチドとしては、分子量分布において、その40重量%以上(遊離アミノ酸は除く)を分子量500以下にしかつ、遊離アミノ酸含量を7重量%以下にすることが望ましく、より望ましくは43重量%以上(遊離アミノ酸は除く)を分子量500以下にしかつ、遊離アミノ酸含量を6重量%以下にする。なお、ここでの分子量はゲルろ過法で測定したものである。より具体的にはTSK社製ゲルろ過カラムを用い、UV検出器を用いて測定したものである。分子量500以下の割合が40重量%未満であったり、また遊離アミノ酸含量が7重量%を超えると、フェニルアラニン-ロイシン-バリンもしくはバリンープロリンーチロシンの配列を持つトリペプチドの含有量が大きく低下してしまう場合がある。
以下、本発明を実施例により詳細に説明する。
分離大豆蛋白(不二製油株式会社製「フジプロR」)の5重量%溶液に対し、サモアーゼ(起源;Bacillus thermoproteolyticus,大和化成)を対たん白質あたり2重量%加え、pH9.0,58℃で60分間作用させた。次にビオプラーゼ(起源;Bacillus sp.,ナガセケムテック)を対たん白質あたり1重量%加え、pH7.5,58℃で60分作用させた。スミチームFP(起源;Aspergillus sp.,新日本化学工業)を対たん白質あたり1重量%加え、pH7.5,58℃で60分作用させた。以上の処理の後、85℃,20分間加熱することで反応を停止した。
また、このペプチド組成物1中、フェニルアラニン-ロイシン-バリンで示されるトリペプチド含量をODSカラムとPAD検出器を用いてHPLCにて測定したところ、3重量%であった。
表2 調製されたペプチド組成物の組成
「潰瘍性大腸炎予防ないし治療試験」
3-5日齢の豚18頭を3群に分けて、3日間飼育した後、試験群(実施例1、比較例1)、対照群(比較例2)として体重1kgあたり1.25gのデキストランサルフェイトを飲料水として5日間与えて(DSS処理)、その後実施例1は、ペプチド組成物1を体重1kg当たり、250mg5日給餌し、比較例1は、ペプチド組成物2を体重1kg当たり、250mg5日給餌し、比較例2はペプチドの窒素含量に相当するアラニンを給餌した。その後解剖を行い、腸管細胞を採取し、サイトカインを測定した。なお、ここでは比較例2がコントロールに相当する。(デキストランサルフェイトは腸管炎症を誘発する物質である。International J. of Colorectal Disease, 15 , 144-160(2000))
TNF-α、IL-6は豚のELISAキット(R&D system Inc.USA)を用いて測定した。
「RT-PCR法によりサイトカインの測定」
IL-17の測定は、mRNAをRNA Mini Kit (Bio-Rad Lab. Inc.)で抽出後cDNA合成キット(Bio-Rad Lab.Inc.)によりcDNAを合 成したのちSYBR Green Spermix(Bio-Rad Lab. Inc.)を用いて測定した。
「吸収されたペプチドの同定」
解剖時において血液を採取し、血漿を分離し、PDA-HPLCにおいて得られたピークをLC-MS/MSにより構造解析を行ってペプチドのアミノ酸配列を同定した。
「優位差検定」
優位差検定はGraphPad Software(USA)を用いて、Tukey-Kramer比較検定を用いた。
・TNF-α、IL-6、IL-17の分析
TNF-α、IL-6、IL-17の分析結果をそれぞれ図2~4に示す。TNF-αの分泌量は、比較例2における分泌量を100%とした場合、比較例1では96%、実施例1では60%であった。またIL-6の分泌量は、比較例2における分泌量を100%とした場合、比較例1では113%、実施例1では43%であった。IL-17の分泌量は、比較例2における分泌量を100%とした場合、比較例1では86%、実施例1では9%であった。以上より、実施例1はTNF-α、IL-6,IL-17とも、比較例2に対し分泌量は20%以上抑制されており、効果ありと判断された。
Tukey-Kramer比較検定による、比較例2との比較の結果、実施例1は有意と判断された(危険率5%以下)。比較例1は有意とは判断されなかった。
・血漿中のペプチドの分析
実施例1の血漿中にはペプチドのピークが3つ存在した。そのうちの最も大きなピークをLC-MS/MSにより構造解析を行ってペプチドのアミノ酸配列を同定したところ、フェニルアラニン-ロイシン-バリンのアミノ酸配列を持つトリペプチドであった。
また、2番目に大きなピークを同様の方法を使ってペプチドのアミノ酸配列を同定したところ、バリンープロリンーチロシンのアミノ酸配列を持つトリペプチドであった。
・組織分析
実施例1、比較例2で、サンプルを供した豚の大腸の組織サンプルの顕微鏡写真を図6,5に示す。図6に示すように、実施例1においては潰瘍がほとんど確認できなかったのに対し、図5の比較例2においては重篤な潰瘍を確認することができた。(比較例1においても比較例2同様の重篤な潰瘍が確認された)。
「合成ペプチドを用いた、細胞実験による炎症性サイトカイン抑制実験」
FLVおよびVPYの合成
FLVの合成は、フェニルアラニン、ロイシン、バリンを原料として、カルボジイミド系の縮合剤を触媒とした有機合成化学的手法を用いて行った。
VPYの合成は、バリン、プロリン、チロシンを原料として、カルボジイミド系の縮合剤を触媒とした有機合成化学的手法を用いて行った。
培養されたCaco-2細胞を3mMのFLVもしくはVPYが存在する5% FBS-DMEM/F12倍地に分散させ、2時間培養した。その後、TNF-αを添加し、4時間培養を行い炎症状態を作りだした。計6時間後に上澄みを取り出し、-80度で一端凍結し、解凍後、炎症性サイトカインIL-8の分析を通常のELISA法によって行った。操作は3回繰り返し、平均値を算出し評価した。
結果を表3に示す。
表3
以上の通り、合成されたトリペプチドFLVおよびVPYは、TNF-αで誘導される、炎症性サイトカインのIL-8の分泌を抑制することがわかった。
・実施例1のように、ペプチド組成物1を投与した豚においては、組織分析によって腸管潰瘍の発生が抑制ないし治癒していることが確認された。同様に、ペプチド組成物2を投与した豚(比較例1)においては、比較例2同様の腸管潰瘍が確認された。このことから、ペプチド組成物1には腸管潰瘍の発生抑制ないし治癒効果を有する成分が存在することが確認された。
・実施例1の豚血漿の分析により、TNF-α、IL-6、IL-17の分泌が抑制されていることが確認され、現在想定されている炎症抑制機構により、豚の腸管潰瘍の発生が抑制、ないし治癒が起こっていることが確認された。
・本実験においては豚における腸管炎症をモデルに実験を行ったが、炎症の抑制および、その際のTNF-α、IL-6、IL-17分泌の挙動は、一般的な抗炎症作用におけるものと同様であった。このことから、本実験で見られた腸管炎症抑制作用は、他の一般的な抗炎症へ適用可能である。
・実施例1の血漿中に存在するペプチドを分析したところ、3種類のペプチドの存在が確認され、これらが、抗炎症の有効成分であると推定された。そのうちのひとつのアミノ酸組成を分析したところ、フェニルアラニン-ロイシン-バリンのアミノ酸配列を持つトリペプチドであることが確認され、このトリペプチドが、抗炎症の有効成分であると推定された。
上記3種類のペプチドのうちのもう一つの組成を分析したところ、バリンープロリンーチロシンのアミノ酸配列を持つトリペプチドであることが確認され、このトリペプチドも、抗炎症の有効成分であると推定された。
・合成ペプチドFLVおよびVPYにおける細胞実験による炎症性サイトカイン抑制実験においても、FLVおよびVPYは、TNF-αで誘導される、炎症性サイトカインのIL-8の分泌を抑制した。この結果は、実施例1の結果を強く支持するものである。
Claims (8)
- 遊離アミノ酸を除く分子量500以下の画分が40重量%以上でありかつ、遊離アミノ酸含量が7重量%以下である、大豆ペプチドである経口性抗炎症機能剤。
- 請求項1記載の抗炎症機能剤を使用する、炎症治療方法。
- 対象とする疾病が腸管炎症である、請求項1記載の経口性抗炎症機能剤。
- アミノ酸配列Phe-Leu-Valで示されるトリペプチド。
- アミノ酸配列Val-Pro-Tyrで示されるトリペプチド。
- 請求項4,5記載のトリペプチドの1種以上を有効成分とする、抗炎症機能剤。
- 請求項4,5記載のトリペプチドの1種以上を有効成分とする、炎症治療方法。
- 請求項4,5記載のトリペプチドの1種以上を有効成分とする、炎症性サイトカイン分泌抑制剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011522753A JP5729297B2 (ja) | 2009-07-13 | 2010-05-12 | 経口性抗炎症剤及び経口性抗炎症ペプチド |
US13/383,673 US20120157395A1 (en) | 2009-07-13 | 2010-05-12 | Anti-inflammatory agent for oral application, and anti-inflammatory peptide for oral application |
CN201080041847.4A CN102665749B (zh) | 2009-07-13 | 2010-05-12 | 口服抗炎剂和口服抗炎肽 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009164323 | 2009-07-13 | ||
JP2009164321 | 2009-07-13 | ||
JP2009-164323 | 2009-07-13 | ||
JP2009-164321 | 2009-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011007612A1 true WO2011007612A1 (ja) | 2011-01-20 |
Family
ID=43449222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/057993 WO2011007612A1 (ja) | 2009-07-13 | 2010-05-12 | 経口性抗炎症剤及び経口性抗炎症ペプチド |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120157395A1 (ja) |
JP (2) | JP5729297B2 (ja) |
CN (1) | CN102665749B (ja) |
WO (1) | WO2011007612A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013133031A1 (ja) * | 2012-03-09 | 2013-09-12 | 森永乳業株式会社 | ジペプチジルペプチダーゼ-iv阻害剤 |
WO2013162202A1 (ko) * | 2012-04-26 | 2013-10-31 | (주)아모레퍼시픽 | 꽃 쌈발효에 의한 항염증용 콩 추출물을 포함하는 조성물 및 제조방법 |
KR20150061933A (ko) * | 2013-11-28 | 2015-06-05 | 부경대학교 산학협력단 | 클라미도모나스 유래 활성 펩타이드를 유효성분으로 포함하는 장 질환 치료 및 예방용 조성물 |
WO2017010538A1 (ja) * | 2015-07-16 | 2017-01-19 | サントリーホールディングス株式会社 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014007547A1 (en) | 2012-07-03 | 2014-01-09 | Il Yang Pharm. Co.,Ltd. | Novel peptides and use thereof |
CN108524907A (zh) * | 2018-07-11 | 2018-09-14 | 河南省南街村(集团)有限公司 | 大豆肽在制备防治气道炎症反应药物中的用途 |
US20230203097A1 (en) * | 2020-05-28 | 2023-06-29 | Mito Quest Co., Ltd. | Novel anti-inflammatory peptide and use thereof |
CN113201046B (zh) * | 2021-06-15 | 2022-11-15 | 北京林业大学 | 一种核桃粕抗炎肽fpy及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004104027A1 (ja) * | 2003-05-21 | 2004-12-02 | Fuji Oil Company, Limited | アンジオテンシン変換酵素阻害ペプチド含有組成物 |
JP2008519831A (ja) * | 2004-11-12 | 2008-06-12 | エヌ.ブイ.・ヌートリシア | 炎症反応を急激に軽減させる食品組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07107078B2 (ja) * | 1991-10-02 | 1995-11-15 | 文男 山内 | 新規なペプチドおよび免疫賦活剤 |
US7244815B2 (en) * | 2001-05-23 | 2007-07-17 | The Curators Of The University Of Missouri | Attachment and elaboration strategies for inverse peptide synthesis |
TWI328457B (en) * | 2003-03-18 | 2010-08-11 | Suntory Holdings Ltd | Angiotensin-converting enzyme inhibitory peptides |
JP2007504144A (ja) * | 2003-08-26 | 2007-03-01 | ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト | セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法 |
US20080004211A1 (en) * | 2004-02-23 | 2008-01-03 | Paul Fraser | Inhibitors of Amyloid Fibril Formation and Uses Thereof |
CN100589702C (zh) * | 2005-09-20 | 2010-02-17 | 中国食品发酵工业研究院 | 一种高纯度、低分子量的大豆低聚肽粉的工业生产方法 |
WO2007066694A1 (ja) * | 2005-12-06 | 2007-06-14 | Fuji Oil Company, Limited | 大豆ペプチド混合物の製造法 |
CN101437517A (zh) * | 2006-04-14 | 2009-05-20 | 夏尔有限责任公司 | 提高共价结合的化合物的镇痛效果、减少其副作用和防止其滥用的组合物和方法 |
US20080207668A1 (en) * | 2006-10-06 | 2008-08-28 | New River Pharmaceuticals Inc. | Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse |
JP2010163400A (ja) * | 2009-01-19 | 2010-07-29 | Kikkoman Corp | 新規アンジオテンシン変換酵素阻害ペプチド |
-
2010
- 2010-05-12 JP JP2011522753A patent/JP5729297B2/ja not_active Expired - Fee Related
- 2010-05-12 CN CN201080041847.4A patent/CN102665749B/zh not_active Expired - Fee Related
- 2010-05-12 WO PCT/JP2010/057993 patent/WO2011007612A1/ja active Application Filing
- 2010-05-12 US US13/383,673 patent/US20120157395A1/en not_active Abandoned
-
2014
- 2014-10-28 JP JP2014218813A patent/JP5892223B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004104027A1 (ja) * | 2003-05-21 | 2004-12-02 | Fuji Oil Company, Limited | アンジオテンシン変換酵素阻害ペプチド含有組成物 |
JP2008519831A (ja) * | 2004-11-12 | 2008-06-12 | エヌ.ブイ.・ヌートリシア | 炎症反応を急激に軽減させる食品組成物 |
Non-Patent Citations (6)
Title |
---|
237TH ACS NATIONAL MEETING, 22 March 2009 (2009-03-22), SALT LAKE CITY, UT, UNITED STATES * |
ABSTRACTS OF PAPERS, 237TH ACS NATIONAL MEETING, 22 March 2009 (2009-03-22), SALT LAKE CITY, UT, UNITED STATES * |
C. MARTINEZ-VILLALUENGA ET AL.: "Protein hydrolysates from p-conglycinin enriched soybean genotypes inhibit lipid accumulation and inflammation in vitro", MOLECULAR NUTRITION AND FOOD RESEARCH, vol. 53, no. 8, August 2009 (2009-08-01), pages 1007 - 1018 * |
DATABASE CAPLUS GONZALEZ DE MEJIA, ET AL.,: "Naturally present soy peptides and their anti-inflammatory activity, Abstracts of Papers", Database accession no. 2009:300772 * |
DATABASE CAPLUS MINE, Y. ET AL.: "Modulation of mucosal cytokine- mediated signaling pathways by dietary peptides: Impact in health promotion, Abstracts of Papers", Database accession no. 2009:300739 * |
HSIN-YI YANG ET AL.: "Soy protein hydrolysate ameliorates cardiovascular remodeling in rats with L-NAME-induced hypertension", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 19, 2008, pages 833 - 839, XP025632426, DOI: doi:10.1016/j.jnutbio.2007.11.004 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013133031A1 (ja) * | 2012-03-09 | 2013-09-12 | 森永乳業株式会社 | ジペプチジルペプチダーゼ-iv阻害剤 |
JPWO2013133031A1 (ja) * | 2012-03-09 | 2015-07-30 | 森永乳業株式会社 | ジペプチジルペプチダーゼ−iv阻害剤 |
EP2824110A4 (en) * | 2012-03-09 | 2015-12-30 | Morinaga Milk Industry Co Ltd | DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
US9617300B2 (en) | 2012-03-09 | 2017-04-11 | Morinaga Milk Industry Co., Ltd. | Dipeptidyl peptidase-IV inhibitor |
WO2013162202A1 (ko) * | 2012-04-26 | 2013-10-31 | (주)아모레퍼시픽 | 꽃 쌈발효에 의한 항염증용 콩 추출물을 포함하는 조성물 및 제조방법 |
KR20150061933A (ko) * | 2013-11-28 | 2015-06-05 | 부경대학교 산학협력단 | 클라미도모나스 유래 활성 펩타이드를 유효성분으로 포함하는 장 질환 치료 및 예방용 조성물 |
KR101633158B1 (ko) | 2013-11-28 | 2016-06-23 | 부경대학교 산학협력단 | 클라미도모나스 유래 활성 펩타이드를 유효성분으로 포함하는 장 질환 치료 및 예방용 조성물 |
WO2017010538A1 (ja) * | 2015-07-16 | 2017-01-19 | サントリーホールディングス株式会社 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
WO2017010133A1 (ja) * | 2015-07-16 | 2017-01-19 | サントリーホールディングス株式会社 | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5729297B2 (ja) | 2015-06-03 |
JP2015038142A (ja) | 2015-02-26 |
US20120157395A1 (en) | 2012-06-21 |
CN102665749B (zh) | 2014-09-17 |
CN102665749A (zh) | 2012-09-12 |
JP5892223B2 (ja) | 2016-03-23 |
JPWO2011007612A1 (ja) | 2012-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5892223B2 (ja) | 経口性抗炎症剤及び経口性抗炎症ペプチド | |
US8354502B2 (en) | Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same | |
JP2008539203A (ja) | 新規栄養補助組成物 | |
EP2380901A1 (en) | Angiotensin converting enzyme inhibitory peptide | |
JP5916387B2 (ja) | ジペプチジルペプチダーゼ−4阻害剤 | |
JP5580273B2 (ja) | 単一の酵素工程における血圧降下ペプチド | |
EP1374885B1 (fr) | Utilisation d'au moins un peptide de la caséine "alphaS2" à activité inhibitrice de l'ACE pour la préparation de médicaments et d'aliments | |
WO2017010538A1 (ja) | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 | |
WO2018021471A1 (ja) | 脳機能改善するための食品組成物 | |
JPH04279597A (ja) | 新規なペプチド及びアンジオテンシン変換酵素阻害ペプチド並びにそれらを含有する経口摂食組成物 | |
JP5130829B2 (ja) | クレアチンホスホキナーゼ分泌抑制組成物 | |
Alauddin et al. | Processed soymilk effectively ameliorates blood pressure elevation in spontaneously hypertensive rats | |
JP2021165290A (ja) | α−グルコシダーゼに関連付けられる病的状態の予防及び/又は治療のための組成物 | |
JP2011036241A (ja) | アンジオテンシン変換酵素阻害ペプチドの製造方法 | |
JP2010024165A (ja) | オキアミタンパク質由来アンジオテンシン変換酵素阻害剤 | |
JP4934369B2 (ja) | 血圧低下作用を有するペプチド | |
JP2873327B2 (ja) | アンジオテンシン変換酵素阻害剤 | |
JP7093954B2 (ja) | サバ由来のペプチドを有効成分とするpai-1阻害剤及び組成物 | |
JPWO2007139128A1 (ja) | クレアチンホスホキナーゼ分泌抑制組成物 | |
EP3170507B1 (en) | Antihypertensive peptides from olive oil | |
TWI414305B (zh) | 腎衰竭預防劑 | |
WO2011145553A1 (ja) | 抗炎症機能剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080041847.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10799674 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011522753 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13383673 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10799674 Country of ref document: EP Kind code of ref document: A1 |